Oxfam report "Investing for Life": Company responses

The Business & Human Rights Resource Centre invited all 12 [pharmaceutical] companies to respond to the report. The results to date are below (any future responses received will be added to this page)...On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses... - Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis responded - Roche, Eli Lilly declined to respond - Bristol-Myers Squibb, Wyeth did not respond

Zeitleiste

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Feb 2008

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

19 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

18 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

18 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Dez 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Oxfam report "Investing for Life": Company responses

Datum:

12 Dez 2007

Inhaltsart:

Artikel

Verfügbare Sprachen: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Datum:

27 Nov 2007

Inhaltsart:

Artikel

Verfügbare Sprachen: español
Oxfam says top drug companies focusing on patents, not poor

Datum:

26 Nov 2007

Inhaltsart:

Artikel

Verfügbare Sprachen: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Datum:

23 Nov 2007

Inhaltsart:

Artikel

Verfügbare Sprachen: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Datum:

12 Nov 2007

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Datum:

1 Nov 2007

Inhaltsart:

Artikel

Verfügbare Sprachen: English

Vollständige Story anzeigen

Mehr laden Weniger anzeigen

Business & Human Rights
Resource Centre

Kontakt (Impressum)

Business & Human Rights Resource Centre

Kontakt (Impressum)

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English

Oxfam report "Investing for Life": Company responses

Zeitleiste

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices